image
Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 3.89
-9.53 %
$ 275 M
Market Cap
-2.25
P/E
1. INTRINSIC VALUE

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities.[ Read More ]

The intrinsic value of one PSNL stock under the base case scenario is HIDDEN Compared to the current market price of 3.89 USD, Personalis, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart PSNL

image
FINANCIALS
73.5 M REVENUE
12.97%
-110 M OPERATING INCOME
4.84%
-108 M NET INCOME
4.43%
-56.3 M OPERATING CASH FLOW
19.90%
13.1 M INVESTING CASH FLOW
-75.07%
11 M FINANCING CASH FLOW
707.54%
25.7 M REVENUE
13.86%
-14.4 M OPERATING INCOME
14.86%
-39.1 M NET INCOME
-205.34%
-6.2 M OPERATING CASH FLOW
42.31%
-28.2 M INVESTING CASH FLOW
-216.89%
62.4 M FINANCING CASH FLOW
4017.81%
Balance Sheet Decomposition Personalis, Inc.
image
Current Assets 147 M
Cash & Short-Term Investments 114 M
Receivables 17.7 M
Other Current Assets 14.8 M
Non-Current Assets 83.2 M
Long-Term Investments 1.79 M
PP&E 75.2 M
Other Non-Current Assets 6.16 M
Current Liabilities 47.2 M
Accounts Payable 14.9 M
Short-Term Debt 9.41 M
Other Current Liabilities 22.9 M
Non-Current Liabilities 48.4 M
Long-Term Debt 39.6 M
Other Non-Current Liabilities 8.87 M
EFFICIENCY
Earnings Waterfall Personalis, Inc.
image
Revenue 73.5 M
Cost Of Revenue 55.3 M
Gross Profit 18.2 M
Operating Expenses 128 M
Operating Income -110 M
Other Expenses -1.64 M
Net Income -108 M
RATIOS
24.78% GROSS MARGIN
24.78%
-149.61% OPERATING MARGIN
-149.61%
-147.38% NET MARGIN
-147.38%
-83.66% ROE
-83.66%
-48.11% ROA
-48.11%
-83.15% ROIC
-83.15%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Personalis, Inc.
image
Net Income -108 M
Depreciation & Amortization 11.3 M
Capital Expenditures -10.9 M
Stock-Based Compensation 14.1 M
Change in Working Capital 13.5 M
Others 24.5 M
Free Cash Flow -67.2 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Personalis, Inc.
image
Wall Street analysts predict an average 1-year price target for PSNL of $6.07 , with forecasts ranging from a low of $3.5 to a high of $9 .
PSNL Lowest Price Target Wall Street Target
3.5 USD -10.03%
PSNL Average Price Target Wall Street Target
6.07 USD 56.08%
PSNL Highest Price Target Wall Street Target
9 USD 131.36%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Personalis, Inc.
image
Sold
0-3 MONTHS
142 K USD 1
3-6 MONTHS
27.1 K USD 3
6-9 MONTHS
6.2 K USD 1
9-12 MONTHS
24.9 K USD 3
Bought
0 USD 0
0-3 MONTHS
17.7 M USD 1
3-6 MONTHS
16.7 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 weeks ago
Nov 01, 2024
Sell 142 K USD
Hall Christopher M
PRESIDENT AND CEO
- 26443
5.38 USD
3 months ago
Aug 16, 2024
Bought 17.7 M USD
Tempus AI, Inc.
10 percent owner
+ 3500000
5.07 USD
3 months ago
Jul 30, 2024
Sell 1.56 K USD
Chen Richard
CHIEF MEDICAL OFFICER AND EVP
- 524
2.97 USD
3 months ago
Jul 30, 2024
Sell 2.2 K USD
Tachibana Aaron
CFO AND COO
- 742
2.97 USD
5 months ago
Jun 17, 2024
Sell 6.52 K USD
Chen Richard
CHIEF MEDICAL OFFICER AND EVP
- 5055
1.29 USD
5 months ago
Jun 17, 2024
Sell 9.26 K USD
Tachibana Aaron
CFO AND COO
- 7176
1.29 USD
5 months ago
Jun 17, 2024
Sell 2.04 K USD
Moore Stephen Michael
SVP and Chief Legal Officer
- 1585
1.29 USD
6 months ago
May 17, 2024
Sell 1.3 K USD
Chen Richard
CHIEF MEDICAL OFFICER AND EVP
- 940
1.38 USD
6 months ago
May 17, 2024
Sell 1.84 K USD
Tachibana Aaron
CFO AND COO
- 1333
1.38 USD
6 months ago
May 17, 2024
Sell 2.39 K USD
Moore Stephen Michael
SVP and Chief Legal Officer
- 1731
1.38 USD
6 months ago
Apr 30, 2024
Sell 6.2 K USD
Moore Stephen Michael
SVP and Chief Legal Officer
- 4523
1.37 USD
8 months ago
Mar 01, 2024
Bought 16.7 K USD
MYERS WOODROW A JR
Director
+ 10000
1.67 USD
9 months ago
Jan 29, 2024
Sell 721 USD
Chen Richard
CHIEF MEDICAL OFFICER AND EVP
- 526
1.37 USD
9 months ago
Jan 29, 2024
Sell 981 USD
Tachibana Aaron
CFO AND COO
- 716
1.37 USD
11 months ago
Dec 15, 2023
Sell 6.92 K USD
Chen Richard
Chief Medical Officer and EVP
- 4708
1.47 USD
11 months ago
Dec 15, 2023
Sell 9.92 K USD
Tachibana Aaron
CFO and COO
- 6747
1.47 USD
11 months ago
Dec 15, 2023
Sell 2.17 K USD
Moore Stephen Michael
General Counsel
- 1476
1.47 USD
1 year ago
Nov 16, 2023
Sell 1.79 K USD
Moore Stephen Michael
General Counsel
- 1722
1.04 USD
1 year ago
Nov 16, 2023
Sell 1.4 K USD
Tachibana Aaron
CFO and COO
- 1344
1.04 USD
1 year ago
Nov 16, 2023
Sell 978 USD
Chen Richard
Chief Medical Officer and EVP
- 940
1.04 USD
1 year ago
Nov 01, 2023
Sell 19 K USD
Hall Christopher M
President and CEO
- 20459
0.93 USD
1 year ago
Jul 31, 2023
Sell 1.5 K USD
Tachibana Aaron
CFO and COO
- 662
2.26 USD
1 year ago
Jul 31, 2023
Sell 1.1 K USD
Chen Richard
Chief Medical Officer and EVP
- 485
2.26 USD
1 year ago
Jun 16, 2023
Sell 3.12 K USD
Moore Stephen Michael
General Counsel
- 1509
2.07 USD
1 year ago
Jun 16, 2023
Sell 9.97 K USD
Chen Richard
Chief Medical Officer and EVP
- 4817
2.07 USD
1 year ago
Jun 16, 2023
Sell 14.3 K USD
Tachibana Aaron
CFO and COO
- 6904
2.07 USD
1 year ago
May 17, 2023
Sell 2.75 K USD
Tachibana Aaron
CFO and COO
- 1389
1.98 USD
1 year ago
May 17, 2023
Sell 3.53 K USD
Moore Stephen Michael
General Counsel
- 1781
1.98 USD
1 year ago
May 17, 2023
Sell 1.92 K USD
Chen Richard
Chief Medical Officer and EVP
- 971
1.98 USD
1 year ago
May 02, 2023
Sell 11.7 K USD
Moore Stephen Michael
General Counsel
- 5102
2.29 USD
1 year ago
Mar 17, 2023
Sell 11.2 K USD
Tachibana Aaron
CFO and COO
- 3945
2.83 USD
1 year ago
Mar 17, 2023
Sell 3.72 K USD
Chen Richard
Chief Medical Officer and EVP
- 1314
2.83 USD
1 year ago
Jan 31, 2023
Sell 1.69 K USD
Tachibana Aaron
Chief Financial Officer
- 767
2.2 USD
1 year ago
Jan 31, 2023
Sell 1.24 K USD
Chen Richard
Chief Medical Officer
- 562
2.2 USD
1 year ago
Dec 20, 2022
Sell 7.38 K USD
Tachibana Aaron
Chief Financial Officer
- 3843
1.92 USD
1 year ago
Dec 20, 2022
Sell 3.36 K USD
Chen Richard
Chief Medical Officer
- 1750
1.92 USD
1 year ago
Dec 15, 2022
Sell 4.82 K USD
Moore Stephen Michael
General Counsel
- 1930
2.5 USD
1 year ago
Dec 15, 2022
Sell 17.9 K USD
Tachibana Aaron
Chief Financial Officer
- 7177
2.5 USD
1 year ago
Dec 15, 2022
Sell 17.9 K USD
Chen Richard
Chief Medical Officer
- 7177
2.5 USD
1 year ago
Dec 02, 2022
Sell 11.3 K USD
Tachibana Aaron
Chief Financial Officer
- 4360
2.6 USD
1 year ago
Dec 02, 2022
Sell 1.14 K USD
Chen Richard
Chief Medical Officer
- 440
2.6 USD
2 years ago
Nov 16, 2022
Sell 3.51 K USD
Chen Richard
Chief Medical Officer
- 1295
2.71 USD
2 years ago
Nov 16, 2022
Sell 3.51 K USD
Tachibana Aaron
Chief Financial Officer
- 1294
2.71 USD
2 years ago
Sep 20, 2022
Sell 12.1 K USD
Tachibana Aaron
Chief Financial Officer
- 3474
3.48 USD
2 years ago
Sep 02, 2022
Sell 1.4 K USD
Chen Richard
Chief Medical Officer
- 420
3.33 USD
2 years ago
Sep 02, 2022
Sell 13.9 K USD
Tachibana Aaron
Chief Financial Officer
- 4168
3.33 USD
2 years ago
Jul 28, 2022
Sell 2.47 K USD
Chen Richard
Chief Medical Officer
- 632
3.91 USD
2 years ago
Jul 28, 2022
Sell 2.47 K USD
Tachibana Aaron
Chief Financial Officer
- 632
3.91 USD
2 years ago
Jun 17, 2022
Sell 5.15 K USD
Chen Richard
Chief Medical Officer
- 1565
3.29 USD
2 years ago
Jun 17, 2022
Sell 11.3 K USD
Tachibana Aaron
Chief Financial Officer
- 3440
3.29 USD
2 years ago
Jun 15, 2022
Sell 5.94 K USD
Moore Stephen Michael
General Counsel
- 1832
3.24 USD
2 years ago
Jun 15, 2022
Sell 22.1 K USD
Chen Richard
Chief Medical Officer
- 6818
3.24 USD
2 years ago
Jun 15, 2022
Sell 22.1 K USD
Tachibana Aaron
Chief Financial Officer
- 6818
3.24 USD
2 years ago
Jun 02, 2022
Sell 15 K USD
Tachibana Aaron
Chief Financial Officer
- 4187
3.59 USD
2 years ago
Jun 02, 2022
Sell 1.51 K USD
Chen Richard
Chief Medical Officer
- 421
3.59 USD
2 years ago
May 16, 2022
Sell 6.25 K USD
Tachibana Aaron
Chief Financial Officer
- 1286
4.86 USD
2 years ago
May 16, 2022
Sell 11.7 K USD
West John Stephen
President and CEO
- 2408
4.86 USD
2 years ago
May 16, 2022
Sell 3.23 K USD
Moore Stephen Michael
General Counsel
- 664
4.86 USD
2 years ago
May 16, 2022
Sell 6.25 K USD
Chen Richard
Chief Medical Officer
- 1286
4.86 USD
2 years ago
May 02, 2022
Sell 31.7 K USD
Moore Stephen Michael
General Counsel
- 5733
5.53 USD
2 years ago
Apr 13, 2022
Sell 0 USD
West John Stephen
President and CEO
- 64430
0 USD
2 years ago
Apr 13, 2022
Sell 477 K USD
West John Stephen
President and CEO
- 64430
7.4 USD
2 years ago
Mar 03, 2022
Bought 2.57 M USD
Lightspeed Venture Partners Select IV, L.P.
other: Affiliate of 10% Owner
+ 261011
9.83 USD
2 years ago
Mar 02, 2022
Bought 488 K USD
Lightspeed Venture Partners Select IV, L.P.
other: Affiliate of 10% Owner
+ 48989
9.96 USD
2 years ago
Mar 02, 2022
Bought 49.3 K USD
Nieh Peter
director:
+ 4750
10.38 USD
2 years ago
Mar 03, 2022
Bought 49.3 K USD
Lightspeed Venture Partners Select IV, L.P.
other: Affiliate of 10% Owner
+ 4750
10.38 USD
2 years ago
Mar 02, 2022
Sell 4.79 K USD
Chen Richard
Chief Medical Officer
- 471
10.18 USD
2 years ago
Mar 02, 2022
Sell 45.9 K USD
Tachibana Aaron
Chief Financial Officer
- 4511
10.18 USD
2 years ago
Jan 28, 2022
Sell 7 K USD
Chen Richard
Chief Medical Officer
- 705
9.93 USD
2 years ago
Jan 28, 2022
Sell 7 K USD
Tachibana Aaron
Chief Financial Officer
- 705
9.93 USD
2 years ago
Jan 18, 2022
Sell 416 K USD
West John Stephen
President and CEO
- 35484
11.73 USD
2 years ago
Jan 19, 2022
Sell 710 K USD
West John Stephen
President and CEO
- 64503
11.01 USD
2 years ago
Dec 17, 2021
Sell 44 K USD
Tachibana Aaron
Chief Financial Officer
- 3437
12.8 USD
2 years ago
Dec 17, 2021
Sell 20 K USD
Chen Richard
Chief Medical Officer
- 1563
12.8 USD
2 years ago
Dec 17, 2021
Sell 35 K USD
West John Stephen
President and CEO
- 2732
12.8 USD
2 years ago
Dec 16, 2021
Sell 1.31 M USD
West John Stephen
President and CEO
- 97268
13.42 USD
2 years ago
Dec 02, 2021
Sell 5.41 K USD
Chen Richard
Chief Medical Officer
- 419
12.92 USD
2 years ago
Dec 02, 2021
Sell 54.1 K USD
Tachibana Aaron
Chief Financial Officer
- 4184
12.92 USD
2 years ago
Nov 30, 2021
Sell 1.36 M USD
West John Stephen
President and CEO
- 100000
13.65 USD
3 years ago
Nov 17, 2021
Sell 40 K USD
West John Stephen
President and CEO
- 2348
17.04 USD
3 years ago
Nov 17, 2021
Sell 21.4 K USD
Tachibana Aaron
Chief Financial Officer
- 1253
17.04 USD
3 years ago
Nov 17, 2021
Sell 21.4 K USD
Chen Richard
Chief Medical Officer
- 1253
17.04 USD
3 years ago
Oct 12, 2021
Sell 1.93 M USD
West John Stephen
President and CEO
- 100000
19.33 USD
3 years ago
Sep 17, 2021
Sell 67 K USD
Tachibana Aaron
Chief Financial Officer
- 3152
21.25 USD
3 years ago
Sep 17, 2021
Sell 23.1 K USD
Chen Richard
Chief Scientific Officer
- 1088
21.25 USD
3 years ago
Sep 02, 2021
Sell 83.7 K USD
Tachibana Aaron
Chief Financial Officer
- 3820
21.92 USD
3 years ago
Sep 02, 2021
Sell 6.38 K USD
Chen Richard
Chief Scientific Officer
- 291
21.92 USD
3 years ago
Aug 06, 2021
Sell 94.1 K USD
Chen Richard
Chief Scientific Officer
- 4436
21.22 USD
3 years ago
Jul 08, 2021
Sell 2.48 M USD
West John Stephen
President and CEO
- 110000
22.54 USD
3 years ago
Jun 17, 2021
Sell 55.1 K USD
Tachibana Aaron
Chief Financial Officer
- 2421
22.75 USD
3 years ago
Jun 17, 2021
Sell 55.1 K USD
Tachibana Aaron
Chief Financial Officer
- 2421
22.75 USD
3 years ago
Jun 17, 2021
Sell 25 K USD
Chen Richard
Chief Scientific Officer
- 1101
22.75 USD
3 years ago
Jun 08, 2021
Sell 2.24 M USD
West John Stephen
President and CEO
- 100050
22.38 USD
3 years ago
Jun 08, 2021
Sell 228 K USD
West John Stephen
President and CEO
- 9950
22.93 USD
3 years ago
Jun 02, 2021
Sell 62.5 K USD
Tachibana Aaron
Chief Financial Officer
- 2899
21.57 USD
3 years ago
Jun 02, 2021
Sell 6.28 K USD
Chen Richard
Chief Scientific Officer
- 291
21.57 USD
3 years ago
Apr 01, 2021
Sell 544 K USD
Chen Richard
Chief Scientific Officer
- 21223
25.61 USD
3 years ago
Apr 01, 2021
Sell 322 K USD
Chen Richard
Chief Scientific Officer
- 12517
25.69 USD
3 years ago
Apr 01, 2021
Sell 163 K USD
Chen Richard
Chief Scientific Officer
- 6260
25.96 USD
3 years ago
Mar 17, 2021
Sell 30.2 K USD
Chen Richard
Chief Scientific Officer
- 1130
26.73 USD
3 years ago
Mar 17, 2021
Sell 65.4 K USD
Tachibana Aaron
Chief Financial Officer
- 2446
26.73 USD
3 years ago
Mar 02, 2021
Sell 98.5 K USD
Tachibana Aaron
Chief Financial Officer
- 3022
32.6 USD
3 years ago
Mar 02, 2021
Sell 11.2 K USD
Chen Richard
Chief Scientific Officer
- 345
32.6 USD
3 years ago
Feb 01, 2021
Sell 249 K USD
Chen Richard
Chief Scientific Officer
- 6519
38.19 USD
3 years ago
Feb 01, 2021
Sell 91.5 K USD
Chen Richard
Chief Scientific Officer
- 2400
38.12 USD
3 years ago
Feb 01, 2021
Sell 428 K USD
Chen Richard
Chief Scientific Officer
- 11022
38.8 USD
3 years ago
Feb 01, 2021
Sell 779 K USD
Chen Richard
Chief Scientific Officer
- 20059
38.83 USD
3 years ago
Dec 17, 2020
Sell 39.5 K USD
Chen Richard
Chief Scientific Officer
- 1087
36.37 USD
3 years ago
Dec 17, 2020
Sell 87 K USD
Tachibana Aaron
Chief Financial Officer
- 2391
36.37 USD
3 years ago
Dec 01, 2020
Sell 399 K USD
Chen Richard
Chief Scientific Officer
- 14388
27.75 USD
3 years ago
Dec 01, 2020
Sell 721 K USD
Chen Richard
Chief Scientific Officer
- 25612
28.14 USD
3 years ago
Dec 02, 2020
Sell 8.13 K USD
Chen Richard
Chief Scientific Officer
- 293
27.76 USD
3 years ago
Dec 02, 2020
Sell 81.2 K USD
Tachibana Aaron
Chief Financial Officer
- 2926
27.76 USD
4 years ago
Oct 20, 2020
Sell 3.61 M USD
Abingworth LLP
- 130486
27.66 USD
4 years ago
Oct 16, 2020
Sell 2.51 M USD
Abingworth LLP
10 percent owner
- 94218
26.68 USD
4 years ago
Oct 19, 2020
Sell 5.47 M USD
Abingworth LLP
10 percent owner
- 196423
27.86 USD
4 years ago
Oct 14, 2020
Sell 2.22 M USD
Abingworth LLP
10 percent owner
- 81925
27.08 USD
4 years ago
Oct 15, 2020
Sell 97.4 K USD
Abingworth LLP
10 percent owner
- 3700
26.32 USD
4 years ago
Oct 12, 2020
Sell 3.36 M USD
Abingworth LLP
10 percent owner
- 115541
29.09 USD
4 years ago
Oct 13, 2020
Sell 2.47 M USD
Abingworth LLP
10 percent owner
- 86819
28.43 USD
4 years ago
Oct 01, 2020
Sell 292 K USD
Chen Richard
Chief Scientific Officer
- 13472
21.67 USD
4 years ago
Oct 01, 2020
Sell 591 K USD
Chen Richard
Chief Scientific Officer
- 26528
22.26 USD
4 years ago
Sep 17, 2020
Sell 25.5 K USD
Chen Richard
Chief Scientific Officer
- 1120
22.74 USD
4 years ago
Sep 17, 2020
Sell 56 K USD
Tachibana Aaron
Chief Financial Officer
- 2463
22.74 USD
4 years ago
Sep 02, 2020
Sell 66.6 K USD
Tachibana Aaron
Chief Financial Officer
- 2899
22.99 USD
4 years ago
Sep 02, 2020
Sell 6.69 K USD
Chen Richard
Chief Scientific Officer
- 291
22.99 USD
4 years ago
Aug 18, 2020
Sell 18.7 M USD
Abingworth LLP
10 percent owner
- 986842
19 USD
4 years ago
Aug 14, 2020
Sell 67.9 K USD
Chen Richard
Chief Scientific Officer
- 3434
19.76 USD
4 years ago
Aug 14, 2020
Sell 552 K USD
Chen Richard
Chief Scientific Officer
- 27366
20.17 USD
4 years ago
Aug 14, 2020
Sell 24.6 K USD
Chen Richard
Chief Scientific Officer
- 1200
20.47 USD
4 years ago
Aug 14, 2020
Sell 271 K USD
LUDLUM KEN
Director
- 13530
20.05 USD
4 years ago
Aug 14, 2020
Sell 271 K USD
LUDLUM KEN
Director
- 13530
20.05 USD
4 years ago
Aug 14, 2020
Sell 132 K USD
LUDLUM KEN
Director
- 6470
20.42 USD
4 years ago
Aug 14, 2020
Sell 132 K USD
LUDLUM KEN
Director
- 6470
20.42 USD
4 years ago
Aug 14, 2020
Bought 25 M USD
Lightspeed Venture Partners Select IV, L.P.
Director
+ 1315789
19 USD
4 years ago
Aug 14, 2020
Bought 25 M USD
Lightspeed Venture Partners Select IV, L.P.
other: Affiliate of 10% Owner
+ 1315789
19 USD
4 years ago
Jun 22, 2020
Sell 13.4 K USD
Chen Richard
Chief Scientific Officer
- 1085
12.37 USD
4 years ago
Jun 05, 2020
Sell 3.9 K USD
Chen Richard
Chief Scientific Officer
- 272
14.34 USD
4 years ago
Jun 01, 2020
Sell 3.81 K USD
Chen Richard
Chief Scientific Officer
- 289
13.19 USD
4 years ago
Jun 02, 2020
Bought 5.32 M USD
Lightspeed Venture Partners Select IV, L.P.
+ 380654
13.98 USD
4 years ago
Jun 01, 2020
Bought 1.01 M USD
Lightspeed Venture Partners Select IV, L.P.
+ 77797
12.98 USD
4 years ago
Mar 09, 2020
Sell 7.84 K USD
Chen Richard
Chief Scientific Officer
- 1000
7.84 USD
4 years ago
Feb 25, 2020
Sell 886 K USD
Chen Richard
Chief Scientific Officer
- 101000
8.77 USD
4 years ago
Mar 02, 2020
Sell 8.76 K USD
Chen Richard
Chief Scientific Officer
- 1000
8.76 USD
4 years ago
Feb 25, 2020
Sell 886 K USD
Chen Richard
Chief Scientific Officer
- 101000
8.77 USD
5 years ago
Jun 24, 2019
Bought 340 K USD
RICCI PAUL
Director
+ 20000
17 USD
5 years ago
Jun 24, 2019
Bought 340 K USD
RICCI PAUL
Director
+ 20000
17 USD
5 years ago
Jun 24, 2019
Bought 1.19 M USD
LUDLUM KEN
Director
+ 70000
17 USD
7. News
Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript seekingalpha.com - 1 week ago
Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates Personalis (PSNL) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.51 per share a year ago. zacks.com - 1 week ago
Personalis to Announce Third Quarter 2024 Financial Results FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its third quarter 2024 financial results on Wednesday, November 6, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic call. businesswire.com - 3 weeks ago
Personalis to Participate at Upcoming Investor Conferences FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will participate at the following investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference Date: Thursday, September 5, 2024 Presentation Time: 4:50 pm Eastern Time Location: Marriott Marquis in New York Lake Street 8th Annual Best Ideas Growth (BIG) Conference Date: Thursday, September 12, 2024 Location: Yale Club. businesswire.com - 2 months ago
Personalis: Resetting My Strategy Following The Q2 Beat PSNL stock has surged from $1.61 to over $4.00 per share following strong Q2 earnings and increased demand for NeXT Personal MRD test. Personalis reported $22.6M in revenue for Q2, with improved gross margins and increased full-year revenue guidance. Personalis secured Medicare coverage, expanded commercial partnerships, showcased product benefits, settled an IP lawsuit, and strengthened market position. seekingalpha.com - 2 months ago
Personalis, Inc. (PSNL) Hit a 52 Week High, Can the Run Continue? Personalis (PSNL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com - 3 months ago
Personalis, Inc. (PSNL) Q2 2024 Earnings Call Transcript Personalis, Inc. (NASDAQ:PSNL ) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Caroline Corner - IR Chris Hall - CEO and President Aaron Tachibana - CFO and COO Rich Chen - CMO and EVP, R&D Conference Call Participants Madison Pasterchick - Morgan Stanley Vidyun Bais - BTIG Thomas Flaten - Lake Street Arthur He - H.C. Wainwright Operator Good day and welcome to the Personalis Second Quarter 2024 Earnings Conference Call. seekingalpha.com - 3 months ago
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates Personalis (PSNL) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.50 per share a year ago. zacks.com - 3 months ago
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) today announced that they have entered into an agreement to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease (MRD). The agreement helps solidify each company's freedom to operate in the MRD market and broadens patient access to the benefits of MRD testing. globenewswire.com - 4 months ago
Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that Chris Hall, CEO and President, will join a panel and speak at the TD Cowen 3rd Annual Tools / Dx Revolution Conference on Tuesday, June 25, 2024 at 5:30 p.m. Eastern Time. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding ca. businesswire.com - 4 months ago
Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it has updated the ASCO data highlights conference call to Friday, June 21, 2024 at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time. Personalis had previously announced it would host the conference call on Wednesday, June 19, 2024 at 1:00 p.m. Pacific Time / 4:00 p.m. Eastern Time. Webcast and Conference Call Information Interested parties may access the call by dia. businesswire.com - 5 months ago
ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) announced today that data presented at the American Society for Clinical Oncology (ASCO) oral podium talks in Chicago, IL demonstrated that the Personalis NeXT Personal test had exceptional detection rates and performance for early-stage breast cancer and immunotherapy monitoring. The NeXT Personal test is the first of a new class of ultra-sensitive liquid biopsy tests designed to detect the earliest traces of cancer recurrence a. businesswire.com - 5 months ago
8. Profile Summary

Personalis, Inc. PSNL

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 275 M
Dividend Yield 0.00%
Description Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
Contact 1330 O’Brien Drive, Menlo Park, CA, 94025 https://www.personalis.com
IPO Date June 20, 2019
Employees 223
Officers Mr. Christopher M. Hall President, Chief Executive Officer & Director Mr. Aaron L. Tachibana Chief Financial Officer & Chief Operating Officer Mr. Stephen M. Moore J.D. Senior Vice President & Chief Legal Officer Dr. Richard Chen M.D., M.S. Executive Vice President of R&D and Chief Medical Officer Dr. Russ B. Altman M.D., Ph.D. Co-Founder and Member of Clinical & Scientific Advisory Board Dr. Euan A. Ashley DPHIL, FRCP, M.D., Ph.D. Co-Founder and Member of Clinical & Scientific Advisory Board Dr. Michael P. Snyder Ph.D. Co-Founder and Member of Clinical & Scientific Advisory Board Mr. Michael J Fitzpatrick Vice President of Worldwide Sales Dr. Christian Haudenschild Ph.D. Senior Vice President of Genomic Laboratory Operations Mr. Stephane Mouradian Ph.D. Senior Vice President of Business Development